Impact of carbapenem selection on resistance and drug cost
What is it about?
The choice of carbapenem used has been linked to different rates of carbapenem resistance. We chose to use a cheaper carbapenem, ertapenem, preferentially as a cost savings initiative. We found no evidence of changing resistance based on carbapenem use over a two year period and saved $20,000 in drug costs.
Why is it important?
Antibiotic stewardship programs and pharmacy departments are often pressured to find cost savings opportunities. The choice of carbapenem can lead to cost savings but there are concerns of the impact of antibiotic resistance. This study shows that in this case, we found substantial savings with no impact on resistance.
The following have contributed to this page: Steven Smoke
In partnership with: